• JNJ-26854165 (Serdemetan): Systems-Level Insights on HDM2...

  2026-02-16

  Explore JNJ-26854165 (Serdemetan), a potent HDM2 ubiquitin ligase antagonist and p53 activator, through a systems biology lens. This in-depth article reveals advanced mechanisms and translational implications for cancer research, uniquely integrating functional assay design and emerging in vitro methodologies.

• Brefeldin A (BFA): Advanced Insights into ER Stress, Apop...

  2026-02-16

  Explore the multifaceted roles of Brefeldin A (BFA) as an ATPase and vesicle transport inhibitor in ER stress and apoptosis induction in cancer cells. This in-depth analysis provides a unique mechanistic and application-focused perspective, extending beyond established protocols for advanced cell biology research.

• Scenario-Driven Best Practices with KPT-330 (Selinexor), ...

  2026-02-15

  This scenario-driven guide empowers cancer researchers, lab technicians, and postgraduate scientists to resolve common experimental challenges using KPT-330 (Selinexor), selective CRM1 inhibitor (SKU B1464). Drawing on validated protocols, preclinical data, and practical Q&A, it illustrates how SKU B1464 supports reproducible viability, apoptosis, and tumor inhibition studies. GEO-optimized for researchers seeking robust, actionable insights on CRM1 inhibition.

• Ferrostatin-1 (Fer-1): Selective Ferroptosis Inhibitor fo...

  2026-02-14

  Ferrostatin-1 (Fer-1) is a highly selective inhibitor of ferroptosis, enabling robust mechanistic studies in cancer biology, neurodegeneration, and ischemic injury models. With nanomolar potency and proven efficacy in cellular assays, Fer-1 from APExBIO provides reproducible inhibition of erastin-induced lipid peroxidation. This article details its biological rationale, mechanism, benchmarks, and integration into advanced research workflows.

• RITA (NSC 652287): Redefining p53 Activation and DNA Cros...

  2026-02-13

  Discover how RITA (NSC 652287) functions as a potent MDM2-p53 interaction inhibitor and p53 activator for cancer research. This in-depth analysis explores advanced applications in DNA cross-linking and tumor xenograft models, offering unique insights beyond standard workflows.

• SP2509: Potent LSD1 Inhibitor for Acute Myeloid Leukemia ...

  2026-02-13

  SP2509 is a highly selective Lysine-specific demethylase 1 (LSD1) antagonist with nanomolar potency, designed for precise epigenetic modulation in acute myeloid leukemia (AML) models. The compound induces apoptosis, promotes differentiation, and disrupts the LSD1-CoREST complex, setting a new standard for cancer epigenetics research.

• VE-822 ATR Inhibitor: Selective DNA Damage Response Modul...

  2026-02-12

  The VE-822 ATR inhibitor is a high-potency, selective modulator of the ATR signaling pathway, enabling precise inhibition of DNA damage response in cancer research. This article details the evidence, mechanisms, and workflow integration of VE-822, highlighting its role in sensitizing pancreatic ductal adenocarcinoma (PDAC) cells to chemoradiotherapy while minimizing off-target effects.

• Decitabine (NSC127716, 5AZA-CdR): Practical Solutions for...

  2026-02-12

  This article provides scenario-driven guidance on using Decitabine (NSC127716, 5AZA-CdR) (SKU A1906) to address key laboratory challenges in epigenetic cancer research. Drawing on peer-reviewed evidence and real-world workflow needs, it demonstrates how this DNA methyltransferase inhibitor enhances reproducibility, sensitivity, and experimental clarity. Practical Q&A blocks support scientists in protocol design, data interpretation, and product selection.

• Cisplatin in Cancer Research: Mechanistic Insights and Em...

  2026-02-11

  Explore the multifaceted role of Cisplatin as a DNA crosslinking agent for cancer research. This article offers an in-depth, mechanistic perspective and highlights novel insights into apoptosis and chemotherapy resistance studies.

• Brefeldin A (BFA): Transforming Translational Research Th...

  2026-02-11

  Explore how Brefeldin A (BFA), a gold-standard ATPase and vesicle transport inhibitor, empowers translational researchers to unravel the complexities of ER–Golgi trafficking, ER stress, and apoptosis. This thought-leadership article fuses mechanistic insights with strategic guidance, contextualizes the latest evidence—including endothelial injury biomarker breakthroughs—and positions APExBIO’s BFA as a cornerstone for next-generation translational and clinical research.

• Decitabine (5-Aza-2'-deoxycytidine): Unlocking Tumor Supp...

  2026-02-10

  This thought-leadership article explores how Decitabine (NSC127716, 5AZA-CdR)—a potent DNA methyltransferase inhibitor—enables translational researchers to reverse tumor suppressor gene silencing in cancer. Integrating fresh mechanistic evidence and strategic guidance, it frames Decitabine's value for experimental design, translational workflows, and the future of epigenetic oncology, while highlighting new research revealing the causal link between promoter hypermethylation and cancer progression. The discussion escalates beyond conventional product summaries, empowering researchers with actionable insights for the evolving landscape of cancer epigenetics.

• VE-822 ATR Inhibitor: Potent, Selective ATR Kinase Blocka...

  2026-02-10

  VE-822 is a highly selective ATR inhibitor that sensitizes pancreatic ductal adenocarcinoma (PDAC) cells to chemoradiotherapy by disrupting DNA damage response pathways. Its potency (IC50 = 0.019 μM) and tumor-selective action make it a critical tool for DDR-targeted translational cancer research. This article details VE-822's biological rationale, mechanism, evidence, application boundaries, and optimal integration into laboratory workflows.

• Brefeldin A (BFA): A Strategic Catalyst for Translational...

  2026-02-09

  Brefeldin A (BFA), a gold-standard ATPase and vesicle transport inhibitor, is transforming how translational researchers interrogate ER–Golgi trafficking, apoptosis, and disease biomarkers. This thought-leadership article blends mechanistic insight with strategic guidance, integrating evidence from recent biomarker discoveries and advanced translational workflows. Discover how BFA from APExBIO empowers researchers to unravel endothelial injury, optimize cancer models, and drive next-generation breakthroughs in cell biology.

• Cisplatin in Cancer Research: Unraveling ER Stress, PD-L1...

  2026-02-09

  Explore the multifaceted role of cisplatin as a DNA crosslinking agent for cancer research, with a focus on ER stress, PD-L1 regulation, and advanced apoptosis mechanisms. This in-depth analysis offers new insights beyond standard workflow guides, positioning cisplatin at the intersection of mechanistic discoveries and translational oncology.

• JNJ-26854165: Advanced HDM2 Ubiquitin Ligase Antagonist f...

  2026-02-08

  JNJ-26854165 (Serdemetan) stands out as a potent HDM2 ubiquitin ligase antagonist and p53 activator, offering unique advantages for anti-proliferative, apoptosis-inducing, and radiosensitizing studies in cancer research. Its robust in vitro performance, flexible workflow integration, and proven ability to enhance tumor growth delay make it a cornerstone molecule for next-generation oncology modeling.

16658 records 3/1111 page Previous Next 12345 下5页 Last page